| __timestamp | Alkermes plc | Ionis Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 447875000 | 241751000 |
| Thursday, January 1, 2015 | 483393000 | 322292000 |
| Friday, January 1, 2016 | 519270000 | 344320000 |
| Sunday, January 1, 2017 | 567637000 | 374644000 |
| Monday, January 1, 2018 | 601826000 | 1820000 |
| Tuesday, January 1, 2019 | 693218000 | 4000000 |
| Wednesday, January 1, 2020 | 572904000 | 12000000 |
| Friday, January 1, 2021 | 603913000 | 11000000 |
| Saturday, January 1, 2022 | 218108000 | 14000000 |
| Sunday, January 1, 2023 | 253037000 | 9133000 |
| Monday, January 1, 2024 | 245331000 | 11215000 |
Unveiling the hidden dimensions of data
In the competitive landscape of biopharmaceuticals, cost efficiency is paramount. Over the past decade, Ionis Pharmaceuticals, Inc. and Alkermes plc have showcased contrasting trends in their cost of revenue. From 2014 to 2023, Alkermes consistently maintained a higher cost of revenue, peaking in 2019 with a 39% increase from 2014. However, a notable decline of 68% was observed by 2022, reflecting strategic shifts or market challenges.
Conversely, Ionis Pharmaceuticals experienced a dramatic fluctuation. After a peak in 2017, their cost of revenue plummeted by 99% in 2018, indicating potential operational restructuring or shifts in product focus. By 2023, Ionis's cost of revenue was approximately 96% lower than its 2017 peak, suggesting a leaner operational model.
These trends highlight the dynamic nature of the biopharma industry, where strategic pivots can significantly impact financial efficiency.
Analyzing Cost of Revenue: Gilead Sciences, Inc. and Ionis Pharmaceuticals, Inc.
Cost Insights: Breaking Down Teva Pharmaceutical Industries Limited and Alkermes plc's Expenses
Viatris Inc. vs Ionis Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Bio-Techne Corporation and Alkermes plc
Analyzing Cost of Revenue: Jazz Pharmaceuticals plc and Alkermes plc
Analyzing Cost of Revenue: Pharming Group N.V. and Alkermes plc
Comparing Cost of Revenue Efficiency: Cytokinetics, Incorporated vs Ionis Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Ionis Pharmaceuticals, Inc. and HUTCHMED (China) Limited
Comparing Cost of Revenue Efficiency: Ionis Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated
Ionis Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Alkermes plc and Ligand Pharmaceuticals Incorporated
Cost of Revenue Comparison: Alkermes plc vs Mesoblast Limited